Research Article
Diagnostic and Prognostic Significance of Serum Biomarkers CA 125 and CA 19-9 in Ovarian Cancer
Issue:
Volume 10, Issue 1, March 2025
Pages:
1-6
Received:
21 December 2024
Accepted:
3 January 2025
Published:
21 January 2025
DOI:
10.11648/j.ijcocr.20251001.11
Downloads:
Views:
Abstract: Background: Ovarian cancer is a significant cause of gynecological cancer-related mortality, with early diagnosis being critical for better outcomes. Serum biomarkers CA 125 and CA 19-9 are widely studied for their diagnostic and prognostic significance in ovarian cancer. Methods: This cross-sectional study analyzed 80 ovarian cancer patients from January to December 2018 at BSMMU, Dhaka. Data included socio-demographic profiles, serum levels of CA 125 and CA 19-9 and their correlation with cancer stage and histological subtypes. Diagnostic performance metrics of CA 125 for advanced stages (III/IV) were also evaluated. Statistical analyses were performed using SPSS. Results: The mean serum CA 125 level was 350.54 ± 120.35 IU/mL, with 85% of cases showing elevated levels. CA 125 levels increased significantly with cancer stage (Stage I: 151 ± 50 IU/mL, Stage IV: 950 ± 305 IU/mL, *p* < 0.001). The mean serum CA 19-9 level was 90.42 ± 45.59 IU/mL, elevated in 40% of cases, with higher levels observed in mucinous subtypes. CA 125 demonstrated high sensitivity (82%) and specificity (75%) for detecting advanced stages. Conclusion: Serum CA 125 is a reliable biomarker for staging and diagnosing advanced ovarian cancer, with CA 19-9 providing additional insights into histological subtypes. These findings reinforce the clinical utility of these biomarkers in managing ovarian cancer.
Abstract: Background: Ovarian cancer is a significant cause of gynecological cancer-related mortality, with early diagnosis being critical for better outcomes. Serum biomarkers CA 125 and CA 19-9 are widely studied for their diagnostic and prognostic significance in ovarian cancer. Methods: This cross-sectional study analyzed 80 ovarian cancer patients from ...
Show More
,
Sadia Jabeen Khan
